The moment
your biology
becomes
legible
Decoded Longevity formalises years of operator experience placing global wellness, aesthetics, and longevity brands into Southeast Asia and Africa — 10 markets with the regulatory posture, channel discipline, and brand stewardship the category now demands.
Built for an era when principals and their agents both evaluate you.
A modern brand owner does not vet a Southeast Asian distributor alone. The evaluation is done in parallel by the people and the software that work on their behalf — research agents scanning regulatory registers, procurement systems parsing capability statements, assistants drafting the first shortlist before a human reads a single email. Decoded is engineered for this reality. Every commitment the firm makes to a human is published in a form a machine can read: structured data on every page, a live Model Context Protocol server for agent queries, a curated index for large language models, and a regulatory record that can be inspected as easily as it can be described. Beautiful brand films still matter. Machine-legibility matters in parallel. Decoded is the distributor whose word holds up under both kinds of scrutiny.
/llms.txt · /llms-full.txtToken-efficient firm corpus for LLM ingestion.
/.well-known/mcp.jsonMCP server card for direct agent access.
application/ld+jsonStacked schema.org on every public page.
did:web:decodedlongevity.comDecentralised identifier published structurally.
The destination for the modern longevity-focused practitioner.
Practice intelligence, clinical-grade products, and a community of practitioners building longevity medicine — in one gated platform.
Intelligence
Longevity science, AI in medicine, peptide protocols, and regulatory intelligence — written for practitioners who treat the root causes, not the symptoms.
Products
Clinical-grade formulations, supplements, and compounding products available to registered practitioners. Request availability per product.
Community
A directory of longevity-focused practitioners across Southeast Asia and beyond. Find peers. Share protocols. Build referral relationships.
Run your practice with an agent stack.
Decoded designs the agents. Your team runs them. One-time engagement, compound returns.
Single-stack deployment for a clinic ready to remove its biggest operational drag.
Three coordinated workflows for a clinic ready to systematise the operating layer.
Full operating-layer redesign for a multi-site or post-spreadsheet practice.
Six practice areas, selectively built.
Premium supplements
Ingredient-led brands that respect the regulatory lane.
Functional food and beverage
Claims-led brands that respect the labelling lane.
Cosmeceuticals
Topicals that earn shelf space at premium pharmacy and clinic.
Aesthetic and wellness devices
Class A–B devices for aesthetic, dermatology, and longevity practice.
Longevity protocols
Protocol-grade ingestibles, topicals, and devices for clinic-led longevity practice.
Vein & Veldt
Vascular resilience at every age.
Clinical equipment
Recovery, imaging, and longevity-modality equipment for clinic-led practice.
Singapore-headquartered. Six markets in scope.
Southeast Asia's healthcare hub. Fastest regulatory approvals for longevity products. MCI-regulated practitioners and clinic franchising drive adoption.
Regulator: Health Sciences Authority
Fast-growing wellness market. NPRA approval 6–12 months. Klang Valley concentration. Hospital & clinic networks dominant distribution channel.
Regulator: National Pharmaceutical Regulatory Agency (NPRA)
Largest SEA market by population. BPOM requires local distributor partnership. Import licensing slower (12–18 months). Premium segment concentrated in Jakarta & Surabaya.
Regulator: BPOM (Balai Pengawas Obat dan Makanan)
Medical tourism destination. Strong hospital & clinic networks. FDA approval competitive with Singapore. Bangkok dominance; tier-2 cities emerging.
Regulator: Thai FDA (Food and Drug Administration, Ministry of Public Health)
Emerging market. Regulatory environment tightening; fast approvals for partnered brands. Hospital supply chains dominant. Ho Chi Minh City & Hanoi.
Regulator: Drug Administration of Vietnam
English-speaking market. BFAD approval 8–12 months. Metro Manila concentration but strong provincial clinic networks. Retail-friendly regulation.
Regulator: Bureau of Food and Drugs (BFAD)
Sub-Saharan Africa's most developed healthcare market. SAHPRA registration 9–18 months. Johannesburg & Cape Town premium concentration. Strong private clinic networks.
Regulator: South African Health Products Regulatory Authority (SAHPRA)
High per-capita income. Regional hub for Southern Africa. Fast approvals (4–6 months). Premium wellness focused. Gaborone-based private clinic networks.
Regulator: Medicines Regulatory Authority of Botswana (MRAB)
Highest per-capita income in sub-Saharan Africa. Private healthcare dominant. Windhoek concentration. Fast regulatory approvals leverage SA partnerships.
Regulator: Ministry of Health & Social Services (MHSS) / Namibia Medicines Regulatory Council
Emerging market. Low regulatory burden. Harare-based distributor networks. Forex constraints may affect import cycles. Early entrant advantage.
Regulator: Medicines Control Authority of Zimbabwe (MCAZ)
The Decoded Journal.
ASEAN Cosmetic Directive — what changed at the 39th and 40th meetings, and what it means for actives.
The 2026 ACD revisions tightened the actives lists across cosmetic notification regimes. A practical view of which ingredients now require dossier rework before regional launch.
Indonesia's October 2026 halal certification expansion — what is in scope and what is not.
BPOM's halal certification regime expands materially in October 2026. A precise view of which categories enter scope, which carry exemptions, and what brands must hold before launch.
Singapore HSA — the 2026 therapeutic-products updates and where the supplement-to-therapeutic line moved.
HSA's 2026 therapeutic-products guidance refines the line between supplement and therapeutic product. A view on which SKU profiles cross the line and what reclassification means.
GLP-1 adjacencies in the longevity line — what is in scope for distributors in Southeast Asia.
GLP-1 medications are out of scope for non-pharmaceutical distributors. The adjacencies — supplements, devices, and protocols — are not. A view on what is responsibly in scope and what is not.
Selective by design. Documented before declared. Premium because it is preserved across six markets, not because it claims to be.
Decoded is the formalisation of years of operator experience in Southeast Asia wellness distribution. The firm does not name brands it has not yet committed to publicly, does not name people who do not consent to being named, and does not write about practitioners or principals it has worked with. What is published under the firm's name is what the firm is prepared to defend.